Responses

Download PDFPDF

Extended report
Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Response to eLetter by Felson and collaborators
    • Jean-Pierre Pelletier, Professor of Medicine, Head - Arthritis Division, University of Montreal, Director - Osteoarthritis
    • Other Contributors:
      • Johanne Martel-Pelletier, Lukas Martin Wildi, Jean-Pierre Raynauld, Andre Beaulieu, Louis Bessette, Frederic Morin, Francois Abram, and Marc Dorais,

    Dear Editor,

    In response to the eLetter of Felson and collaborators, we wish to point out that the methodologies used in the present study have been extensively validated and found to be reliable in the context of multicenter clinical trials [1-3]. Most of the comments made by Felson and collaborators reflect their experience from observational studies which may or may not apply to clinical trials.

    Regarding the...

    Show More
    Conflict of Interest:
    None declared.